blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2019683

EP2019683 - ADMINISTRATION OF GROWTH FACTORS FOR THE TREATMENT OF CNS DISORDERS [Right-click to bookmark this link]
StatusPatent maintained as amended
Status updated on  01.07.2022
Database last updated on 09.04.2026
FormerThe patent has been granted
Status updated on  11.11.2016
FormerGrant of patent is intended
Status updated on  04.11.2016
Most recent event   Tooltip01.07.2022Patent maintained (B2 publication)published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
The Regents of the University of California
1111 Franklin Street, 12th Floor
Oakland, CA 94607 / US
[2016/50]
Former [2009/06]For all designated states
The Regents of the University of California
1111 Franklin Street, 12th Floor
Oakland, CA 94607-5200 / US
Inventor(s)01 / BANKIEWICZ, Krystof, S.
5815 Balmoral Drive
Oakland, CA 94619 / US
 [2009/06]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[2022/31]
Former [2016/50]Brasnett, Adrian Hugh, et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
Former [2009/06]Brasnett, Adrian Hugh, et al
Mewburn Ellis LLP 33 Gutter Lane London
EC2V 8AS / GB
Application number, filing date07761286.925.04.2007
[2009/06]
WO2007US67423
Priority number, dateUS20060795012P25.04.2006         Original published format: US 795012 P
[2009/06]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2007127803
Date:08.11.2007
Language:EN
[2007/45]
Type: A2 Application without search report 
No.:EP2019683
Date:04.02.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 08.11.2007 takes the place of the publication of the European patent application.
[2009/06]
Type: B1 Patent specification 
No.:EP2019683
Date:14.12.2016
Language:EN
[2016/50]
Type: B2 New European patent specification 
No.:EP2019683
Date:03.08.2022
Language:EN
[2022/31]
Search report(s)International search report - published on:US23.10.2008
(Supplementary) European search report - dispatched on:EP12.07.2010
ClassificationIPC:A61K9/00, A61K49/18, A61K33/24, A61K49/04, A61K51/12, A61K38/18, A61K48/00
[2016/21]
CPC:
A61K38/18 (EP,US); A61K33/242 (EP,US); A61K33/244 (EP,US);
A61K38/185 (EP,US); A61K48/0083 (EP,US); A61K49/0466 (EP,US);
A61K49/1812 (EP,US); A61K51/1234 (US); A61K9/0085 (EP,US);
A61P25/00 (EP); A61P25/08 (EP); A61P25/14 (EP);
A61P25/16 (EP); A61P25/18 (EP); A61P25/28 (EP);
A61P27/02 (EP); A61P3/04 (EP); A61P43/00 (EP);
A61P9/10 (EP); C12N2750/14143 (EP,US) (-)
C-Set:
A61K33/24, A61K2300/00 (EP,US)
Former IPC [2010/32]A61K39/00, A61K38/18
Former IPC [2009/06]A61K39/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/50]
Former [2009/06]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesALNot yet paid
BANot yet paid
HRNot yet paid
MKNot yet paid
RSNot yet paid
TitleGerman:VERABREICHUNG VON WACHSTUMSFAKTOREN ZUR BEHANDLUNG VON ZNS-ERKRANKUNGEN[2009/06]
English:ADMINISTRATION OF GROWTH FACTORS FOR THE TREATMENT OF CNS DISORDERS[2009/06]
French:ADMINISTRATION DE FACTEURS DE CROISSANCE POUR TRAITER DES TROUBLES DU SNC[2009/06]
Entry into regional phase25.11.2008National basic fee paid 
25.11.2008Search fee paid 
25.11.2008Designation fee(s) paid 
25.11.2008Examination fee paid 
Examination procedure25.11.2008Examination requested  [2009/06]
08.02.2011Amendment by applicant (claims and/or description)
28.03.2013Despatch of a communication from the examining division (Time limit: M06)
27.08.2013Reply to a communication from the examining division
30.10.2014Despatch of a communication from the examining division (Time limit: M06)
11.05.2015Reply to a communication from the examining division
28.01.2016Despatch of a communication from the examining division (Time limit: M04)
14.04.2016Reply to a communication from the examining division
13.05.2016Communication of intention to grant the patent
22.09.2016Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
22.09.2016Fee for grant paid
22.09.2016Fee for publishing/printing paid
04.11.2016Information about intention to grant a patent
04.11.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  28.03.2013
Opposition(s)Opponent(s)01  13.09.2017  19.09.2017  ADMISSIBLE
Herantis Pharma Oyj
Bertel Jungin aukio 1
02600 Espoo / FI
Opponent's representative
Laine IP Oy
Porkkalankatu 24
00180 Helsinki / FI
 [2021/13]
Former [2019/52]
Opponent(s)01  13.09.2017  19.09.2017  ADMISSIBLE
Herantis Pharma Oyj
Viikinkaari 4
00790 Helsinki / FI
Opponent's representative
Seppo Laine Oy
Porkkalankatu 24
00180 Helsinki / FI
Former [2017/43]
Opponent(s)01  13.09.2017  19.09.2017  ADMISSIBLE
Herantis Pharma Oyj
Viikinkaari 4
00790 Helsinki / FI
Opponent's representative
Seppo Laine Oy
Itämerenkatu 3 A
00180 Helsinki / FI
23.10.2017Invitation to proprietor to file observations on the notice of opposition
01.03.2018Reply of patent proprietor to notice(s) of opposition
05.03.2019Date of oral proceedings
12.04.2019Despatch of minutes of oral proceedings
15.04.2019Despatch of interlocutory decision in opposition
24.01.2022Legal effect of interlocutory decision in opposition
17.03.2022Despatch of communication that the patent will be maintained as amended
23.06.2022Fee for printing new specification paid
Appeal following opposition24.06.2019Appeal received No.  T1910/19
23.08.2019Statement of grounds filed
24.01.2022Result of appeal procedure: appeal of the opponent withdrawn
24.06.2019Appeal received No.  T1910/19
22.08.2019Statement of grounds filed
22.12.2020Invitation to file observations in an appeal (Time limit: M02) [2020/52]
24.01.2022Result of appeal procedure: appeal of the opponent withdrawn
Fees paidRenewal fee
29.04.2009Renewal fee patent year 03
26.04.2010Renewal fee patent year 04
25.04.2011Renewal fee patent year 05
28.03.2012Renewal fee patent year 06
29.04.2013Renewal fee patent year 07
28.04.2014Renewal fee patent year 08
27.04.2015Renewal fee patent year 09
27.04.2016Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY14.12.2016
EE14.12.2016
LT14.12.2016
LV14.12.2016
MC14.12.2016
IS14.04.2017
MT25.04.2017
[2019/46]
Former [2018/43]EE14.12.2016
LT14.12.2016
LV14.12.2016
MC14.12.2016
IS14.04.2017
MT25.04.2017
Former [2018/06]EE14.12.2016
LT14.12.2016
LV14.12.2016
MC14.12.2016
IS14.04.2017
Former [2017/43]EE14.12.2016
LT14.12.2016
LV14.12.2016
IS14.04.2017
Former [2017/28]LT14.12.2016
LV14.12.2016
Former [2017/12]LV14.12.2016
Documents cited:Search[X] WO2005120548  (STREATFIELD GILL STEVEN et al.)
 [X] WO2006044115  (AMGEN INC et al.) [X] 1,2,11 * page 33, line 14 - page 34, line 14 * * page 38, line 16 - line 26 * * claim - *
 [X] WO2004075720  (NORTH BRISTOL N H S TRUST et al.)
 [X]   HAMILTON J F ET AL: "Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin", EXPERIMENTAL NEUROLOGY, ACADEMIC PRESS, NEW YORK, NY, US LNKD- DOI:10.1006/EXNR.2000.7571, vol. 168, no. 1, 1 March 2001 (2001-03-01), pages 155 - 161, XP002409643, ISSN: 0014-4886

DOI:   http://dx.doi.org/10.1006/exnr.2000.7571
 [X]   KIRIK DENIZ ET AL: "Localized striatal delivery of GDNF as a treatment for Parkinson disease", NATURE NEUROSCIENCE, NATURE AMERICA, INC, US LNKD- DOI:10.1038/NN1175, vol. 7, no. 2, 1 February 2004 (2004-02-01), pages 105 - 110, XP002343709, ISSN: 1097-6256

DOI:   http://dx.doi.org/10.1038/nn1175
 [X]   GILL S S ET AL: "Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US LNKD- DOI:10.1038/NM850, vol. 9, no. 5, 1 May 2003 (2003-05-01), pages 589 - 595, XP002343708, ISSN: 1078-8956 [X] 1,2,4,11 * the whole document *

DOI:   http://dx.doi.org/10.1038/nm850
 [A]   MASWOOD N ET AL: "Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys", NEUROBIOLOGY OF AGING, TARRYTOWN, NY, US LNKD- DOI:10.1016/S0197-4580(02)00022-2, vol. 23, no. 5, 1 January 2002 (2002-01-01), pages 881 - 889, XP002293324, ISSN: 0197-4580 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0197-4580(02)00022-2
 [XP]   BRUNDIN PATRIK: "GDNF treatment in Parkinson's disease: Time for controlled clinical trials?", BRAIN, OXFORD UNIVERSITY PRESS, OXFORD, GB LNKD- DOI:10.1093/BRAIN/AWF217, vol. 125, no. 10, 1 October 2002 (2002-10-01), pages 2149 - 2151, XP002293327, ISSN: 0006-8950

DOI:   http://dx.doi.org/10.1093/brain/awf217
 [A]   SLEVIN JOHN T ET AL: "Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor", JOURNAL OF NEUROSURGERY, AMERICAN ASSOCIATION OF NEUROLOGICAL SURGEONS, US LNKD- DOI:10.3171/JNS.2005.102.2.0216, vol. 102, no. 2, 1 February 2005 (2005-02-01), pages 216 - 222, XP002427990, ISSN: 0022-3085

DOI:   http://dx.doi.org/10.3171/jns.2005.102.2.0216
 [A]   GRONDIN R ET AL: "CHRONIC, CONTROLLED GDNF INFUSION PROMOTES STRUCTURAL AND FUNCTIONAL RECOVERY IN ADVANCED PARKINSONIAN MONKEYS", BRAIN, OXFORD UNIVERSITY PRESS, OXFORD, GB LNKD- DOI:10.1093/BRAIN/AWF234, vol. 125, no. PART 10, 1 October 2002 (2002-10-01), pages 2191 - 2201, XP009035486, ISSN: 0006-8950 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1093/brain/awf234
International search[X] US2002114780  (BANKIEWICZ KRYS et al.)
 [XE] US7371225  (OLDFIELD EDWARD H et al.)
by applicantUS6042579
 US2006073101
 US5720720
 US2002114780
   SAITO ET AL., EXP. NEUROL., vol. 196, 2005, pages 3891 - 389
   KRAUZE ET AL., EXP. NEUROL., vol. 196, 2005, pages 104 - 111
   KRAUZE ET AL., BRAIN RES. BRAIN RES. PROTOCOL., vol. 16, 2005, pages 20 - 26
   CUNNINGHAM; WELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085
   HADACZEK ET AL., HUMAN GENE THERAPY, vol. 17, 2006, pages 1 - 12
   SCIENCE, vol. 260, 1993, pages 1130 - 1132
   KRIEGLSTEIN ET AL., EMBO J., vol. 14, 1995, pages 736 - 742
   POULSEN ET AL., NEURON, vol. 13, 1994, pages 1245 - 1252
   LIN ET AL., SCIENCE, vol. 260, 1993, pages 1130 - 1132
   HUDSON ET AL., BRAIN RES. BULL, vol. 36, 1995, pages 425 - 432
   BECK ET AL., NATURE, vol. 373, 1995, pages 339 - 341
   TOMAC ET AL., NATURE, vol. 373, 1995, pages 335 - 339
   HOFFER ET AL., NEUROSCI. LETT, vol. 182, 1994, pages 107 - 111
   OPPENHEIM ET AL., NATURE, vol. 373, 1995, pages 344 - 346
   ZURN ET AL., NEUROREPORT, vol. 6, 1994, pages 113 - 118
   YAN ET AL., NATURE, vol. 373, 1995, pages 341 - 344
   HENDERSON ET AL., SCIENCE, vol. 266, 1994, pages 1062 - 1064
   SARIOLA ET AL., J. CELL SCI., vol. 116, 1 October 2003 (2003-10-01), pages 3855 - 62
   VENERO ET AL., NEUROREPORT, vol. 4, 1993, pages 959 - 962
   HEFTI, J. NEUROBIOL, vol. 25, 1994, pages 1418 - 1435
   OLSON, NEUROCHEM, 1994, pages 1 - 3
   BATCHELOR ET AL., J. COMP. NEUROL., vol. 284, 1989, pages 187 - 204
   KISS ET AL., NEUROSCI., vol. 27, 1988, pages 731 - 748
   WOOLF ET AL., NEUROSCI, vol. 30, 1989, pages 143 - 152
   SELKOE, NEURON, vol. 6, 1991, pages 487 - 498
   PETTY ET AL., ANN. AUG, vol. 36, 1994, pages 244 - 246
   ESLAMBOLI, REV. NEUROSCI, vol. 16, no. 4, 2005, pages 303 - 10
   KORDOWER ET AL., ANN. NEUROL., vol. 46, 1999, pages 419 - 424
   GILL ET AL., NAT. MED., vol. 9, 2003, pages 5899 - 595
   PATEL ET AL., ANN. NEUROL., vol. 57, 2005, pages 298 - 302
   LANG ET AL., ANN. NEUROL., vol. 59, 2006, pages 459 - 466
   ESLAMBOLI, REV. NEUROSCI., vol. 16, no. 4, 2005, pages 303 - 10
   KRAUZE ET AL., EXP NEUROL., vol. 196, no. 1, November 2005 (2005-11-01), pages 104 - 11
OppositionUS2002114780
 US2002114780
   CHRISTIAN WINKLER ET AL.: "Short-Term GDNF Treatment Provides Long-Term Rescue of Lesioned Nigral Dopaminergic Neurons in a Rat Model of Parkinson's Disease", THE JOURNAL OF NEUROSCIENCE, vol. 16, no. 22, 15 November 1996 (1996-11-15), pages 7206 - 7215, XP055419561

DOI:   http://dx.doi.org/10.1523/JNEUROSCI.16-22-07206.1996
   LINDAHL ET AL.: "Unconventional neurotrophic factors CDNF and MANF: Structure, physiological functions and therapeutic potential", NEUROBIOLOGY OF DISEASE, vol. 97, 2017, pages 90 - 102, XP029839509

DOI:   http://dx.doi.org/10.1016/j.nbd.2016.07.009
   CHRISTIAN WINKLER ET AL.: "Short-Term GDNF Treatment Provides Long-Term Rescue of Lesioned Nigral Dopaminergic Neurons in a Rat Model of Parkinson's Disease", THE JOURNAL OF NEUROSCIENCE, vol. 16, no. 22, 15 November 1996 (1996-11-15), pages 7206 - 7215
   LINDAHL ET AL.: "Unconventional neurotrophic factors CDNF and MANF: Structure, physiological functions and therapeutic potential", NEUROBIOLOGY OF DISEASE, vol. 97, 2017, pages 90 - 102
   Bobo et al, 1994, PNAS 91:2076-80 [X] 1,2,4,11 * the whole document *
   Morrison et al, 1994, Am.J.Physiol. 266: R292-R305
   Allard et al, 2009, Biomaterials 30: 2302-18 [X] 1,11-14 * the whole document * * page 108, column l * * page 109, column l *
   Schober, Cell Tissue Res., 2004, 318: 215-224 [A] 1-15 * the whole document *
   Grodin et al, 2002, Brain, 125: 2119-2201
   Gill et al. 2003. Nature Medicine. 9(5): 589-95
   Slevin et al, 2005, J Neurosurg 102: 216-22 [A] 1-15 * the whole document *
   Lang et al, 2006, Ann Neurol 59: 459-66 [A] 1-15 * the whole document *
   Patel and Gill, 2007, Acta Neurochir Suppl 97(2): 135-154 [A] 1-15 * the whole document *
   Morrison et al. 2007, J Neurosurg 107: 74-83 [A] 1-15 * the whole document *
   Salvatore et al, 2006, Exp Neurol 202: 497-505
   Sherer et al, 2006, Movement Disorders 21(2): 136-41
   Hadaczek et al, 2010, Neuropharmacology 58: 1114-21
   Taylor et al, 2013, PLOS One 8(3):e56186, p. 1 -9
   http://www.medlink.com/article/neurotrophic-factors
   Argente-Arizon et al, 2015, Fronteers in Endocrinology 6, article 42, p.1-15
   PubMed abstract of Gold, 2000, Expert Opin Investig Drugs 9(10): 2331-42
   McGeachie et al, 1997, Australian Dental Journal 42(6):375-80
   Hamilton et al. Experimental Neurology 168, 155-161 (2001)
   Guo et al, 2001, Ann Neurol 50: 6-16
   Poulter et al, 2004, Neuroscience 128: 1-6
   Huttunen, H and M Saarma (2019) Cell transplantation 28(4):349-366
   Mocchetti, I. (2005) Cell. Mol. Life Sci. 62:2283-94
   Fusco, M. et al (1993) Ann. NY. Acad. Sci 695:314-7
   Lim, S T et al (2011) Neuropharmacology 60:1160-7
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.